Skye Bioscience, Inc.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
SKYE$0.84+21.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of (Unaudited) and
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30,2025 | December 31,2024 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $18,441,079 | $68,415,741 |
| Short-term investments | 16,871,229 | — |
| Prepaid expenses | 3,712,311 | 201,962 |
| Other current assets | 900,175 | 2,209,544 |
| Total current assets | 39,924,794 | 70,827,247 |
| Property and equipment, net | 1,033,965 | 1,432,752 |
| Operating lease right-of-use asset | 311,620 | 449,864 |
| Other assets | 53,910 | 53,910 |
| Total assets | $41,324,289 | $72,763,773 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable | $2,825,005 | $569,252 |
| Accrued payroll liabilities | 920,774 | 1,114,255 |
| Other current liabilities | 2,366,123 | 654,201 |
| Estimate for accrued legal contingencies and related expenses | 2,054,357 | 1,818,751 |
| Operating lease liability, current portion | 201,638 | 182,428 |
| Total current liabilities | 8,367,897 | 4,338,887 |
| Non-current liabilities | ||
| Operating lease liability, net of current portion | 120,207 | 273,162 |
| Total liabilities | 8,488,104 | 4,612,049 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value; 200,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value; 100,000,000 shares authorized at September 30, 2025 and December 31, 2024; 30,989,046 and 30,974,559 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 30,989 | 30,975 |
| Additional paid-in-capital | 205,237,719 | 199,070,421 |
| Accumulated deficit | (172,432,523) | (130,949,672) |
| Total stockholders’ equity | 32,836,185 | 68,151,724 |
| Total liabilities and stockholders’ equity | $41,324,289 | $72,763,773 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.